ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1541
주식 순위
#19245
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
주가
$0.38122017
마지막 동기화: 2026-10-16
시가총액
$159.74M
변동 (1일)
2.58%
변동 (1년)
-71.65%
국가
CN
거래 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
카테고리
Healthcare
의 시가총액 ImmuneOnco Biopharmaceuticals (Shanghai) Inc.(1541)
시가총액: $159.74M
October 2026 기준으로 ImmuneOnco Biopharmaceuticals (Shanghai) Inc.의 시가총액은 $159.74M입니다. 이는 당사 데이터에 따르면 ImmuneOnco Biopharmaceuticals (Shanghai) Inc.이 세계에서 19245th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2023부터 2026까지 ImmuneOnco Biopharmaceuticals (Shanghai) Inc.의 시가총액 기록
